Alicia Bigica

The Infinity DBS system is the only directional DBS system approved to target all major areas associated with movement disorders, including Parkinson disease and essential tremor.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Donald Frei, MD.

Donald Frei, MD, a neurointerventional surgeon in Colorado, recently appealed to the National EMS Advisory Council for improved EMS triage and transport protocols.

The FDA approved an updated drug label for the multiple sclerosis drug, including updates on immunizations and risks in specific patient populations.

The drug, which is a schedule IV controlled substance, is the first nasal spray approved as rescue medication in patients 6 years and older with epilepsy.

The proprietary formulation of aspirin and fumaric acid addresses issues with pretreating fumarate flush, a bothersome side effect of popular MS disease-modifying therapy Tecfidera.

The findings suggest that the communicated risk may only apply to patients with very recent ischemic stroke.

The approvals introduced several new classes of drugs, including the ditans and gepants in migraine, as well as novel formulations that can ease the administration of treatments for Parkinson disease and epilepsy.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Daniel Lowenstein, MD.

WVE-120102 is the first allele-selective molecule that preferentially lowers mHTT protein by targeting SNP2 in order to maintain levels of healthy or wild-type HTT protein.

The vice president and chief medical officer of the Neurology Business Group at Eisai discussed the company's decision to continue efforts on amyloid therapy despite prior setbacks.

Catch up on some of our most popular video interviews with leaders in the field, including discussions with Imad Najm, MD, James Leverenz, MD, Richard Isaacson, MD, and more.

Karl Doghramji, MD, medical director of the Jefferson Sleep Disorders Center, reviews optimal management strategies for elderly patients with insomnia disorder.

The small-molecule dual orexin receptor antagonist was approved based on data from 2 pivotal phase 3 studies which showed statistical superiority over placebo for sleep onset latency.

Two lots of the oral seizure treatment have been recalled and should be returned to the manufacturer.

The drug safety warning stems from a review of case reports and clinical studies that showed use of gabapentinoids with or without opioids is associated with serious breathing difficulties.

CENTAUR trial principal investigator Sabrina Paganoni, MD, PhD, discussed details of the phase 2 trial that helped investigators have the greatest chance of seeing a measurable treatment effect in patients with ALS.

Top-line results from the phase 2 CENTAUR trial showed a statistically significant slowing of ALS disease progression in patients treated with AMX0035.

A survey by the ALS Association found that 26% of patients reported having a PEG tube, which are typically inserted to allow for continued administration of nutrition, fluids, and medications as the disease progresses.

Laboratories in the US are now authorized to add the GSP Neonatal Creatine Kinase-MM kit to their newborn screening panels if they choose to do so.

Full results from the single-dose crossover study requested by the FDA were reported at AES 2019, along with multi-dose safety and efficacy data.

NeurologyLive will be providing live coverage of AES 2019 from Baltimore beginning Saturday, December 7.

The assistant professor of clinical neurology at Keck School of Medicine University of Southern California in Los Angeles sat down with NeurologyLive for a Q&A discussing using steroids as treatment for multiple sclerosis.

The approval is supported by several studies which demonstrated the drug’s bioequivalence to Rilutek, the liquid riluzole formulation marketed by Sanofi.

Alireza Atri, MD, PhD, medical director of the Banner Sun Health Research Institute, spoke about the importance of open-ended cognitive screening, and the value that early detection and intervention can bring to the table.

This is the third safety incident in the IGNITE DMD clinical trial that has resulted in a clinical hold since its inception in 2017.

The chief medical executive at The University of Texas MD Anderson Cancer Center is expected to be named the next commissioner of the FDA by President Donald Trump.

In an interview with NeurologyLive, Andrew S. Feigin, MD, details ongoing trials that aim to treat Huntington disease, including the notable SIGNAL trial.

The drug, which is currently approved for single-dose intravenous administration in patients with SMA type 1, is currently being investigated as intrathecal therapy in SMA type 2.

After pulling the plug on trials in March 2019, Biogen has announced that an expanded analysis revealed significant positive results for aducanumab in patients with early Alzheimer disease.